Helix Biopharma Corp.
HBPCF
$1.71
-$0.02-1.16%
OTC PK
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 57.82% | 49.31% | 45.19% | -51.20% | -70.26% |
| Total Depreciation and Amortization | -47.87% | -45.10% | -30.39% | -21.82% | -8.74% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -94.15% | -90.46% | -99.34% | 623.67% | 601.33% |
| Change in Net Operating Assets | -89.71% | -80.90% | 176.66% | 708.08% | 321.60% |
| Cash from Operations | 0.25% | 4.06% | 28.85% | 36.90% | 43.66% |
| Capital Expenditure | 100.00% | 6.67% | 86.41% | 69.79% | 69.79% |
| Sale of Property, Plant, and Equipment | -100.00% | 30.51% | -- | 267.57% | 267.57% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -100.00% | 43.18% | 218.45% | 284.48% | 284.48% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -68.19% | 57.94% | -49.16% | -28.91% | 46.91% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -68.40% | 52.67% | -51.37% | -30.69% | 45.58% |
| Foreign Exchange rate Adjustments | -- | -- | -- | 350.68% | 85.07% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -206.16% | 117.38% | -492.21% | 97.66% | 166.03% |